NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-31
Reading DHR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Increase adjusted EPS to $8.35-$8.55 in 2026: EPS guidance $8.45-$8.60 vs target $8.35-$8.55.
View ThesisRevenue is growing steadily — about 5% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskDanaher aims to grow core revenue by 3% to 6% in 2026. The company recently raised its adjusted EPS guidance to $8.45-$8.60. It trades at 24× P/E, below the peer median of 32×. This suggests the price reflects less growth than expected. A specific risk is that guidance may be cut, with a 14% miss probability. Peer multiples imply a price roughly in line with where it trades. This read is provisional; the thesis is on watch.
Trailing returns as of 2026-07-31. DHR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 27 analysts currently covering DHR (as of Jul 2026).
Based on 12 Wall Street analysts offering 12-month price targets for DHR in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Advances: Increase adjusted diluted EPS guidance for 2026
Beating EPS forecast supports growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $194.98
The last 12 months of price, then the range of analyst 12-month targets from today’s $194.98.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Price target cut indicates potential revenue growth issues.
Advances: Grow core revenue 3% to 6%
Increased EPS guidance supports growth objective.
Threatens: Grow core revenue 3% to 6%
Mixed results indicate potential challenges in achieving revenue growth.
Threatens: Increase EPS guidance
Earnings beat but share decline raises concerns.
Abbott's success indicates competitive pressure on Danaher's biotech segment.
Threatens: Grow core revenue 3% to 6%
Recovery fell short, impacting growth expectations.
Advances: Increase EPS guidance
Earnings beat estimates, supporting EPS guidance.
